Javlor (vinflunine ditartrate)
July 6, 2015
Javlor (vinflunine ditartrate)
binds to tubulin at or near to the
vinca binding sites inhibiting its
polymerisation into microtubules,
which results in treadmilling
suppression, disruption of
microtubule dynamics, mitotic
arrest and apoptotic cell death.
Javlor is indicated in the treatment
of adult patients with advanced
or metastatic transitional cell
carcinoma of the urothelial
tract after failure of a prior
platinum containing regimen. It is
contraindicated in hypersensitivity
to vinca alkaloids, recent (within 2
weeks) or current severe infection,
baseline absolute neutrophil
count (ANC) < 1.5 x 109/L for
the first administration, baseline
ANC < 1.0 x 109/L for subsequent
administrations, platelets < 100 x
109/L and also in lactation. 1 mL of
Javlor contains 25 mg of vinflunine
(as vinflunine ditartrate). Javlor
concentrated injection is available
as 50 mg/2 mL and 250 mg/10 mL
vials in packs of 1’s and 10’s.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 15
